Your browser doesn't support javascript.
loading
Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model
Duzgun, Ozgul; Sarici, Inanc Samil; Gokcay, Serkan; Ates, Kivilcim Eren; Yılmaz, Mehmet Bertan.
  • Duzgun, Ozgul; Umraniye Training and Research Hospital. Department of Surgical Oncology. Istanbul. TR
  • Sarici, Inanc Samil; Umraniye Training and Research Hospital. Department of Surgical Oncology. Istanbul. TR
  • Gokcay, Serkan; Umraniye Training and Research Hospital. Department of Surgical Oncology. Istanbul. TR
  • Ates, Kivilcim Eren; Umraniye Training and Research Hospital. Department of Surgical Oncology. Istanbul. TR
  • Yılmaz, Mehmet Bertan; Umraniye Training and Research Hospital. Department of Surgical Oncology. Istanbul. TR
Acta cir. bras ; 32(12): 1006-1012, Dec. 2017. tab, graf
Article in English | LILACS | ID: biblio-886195
ABSTRACT
Abstract

Purpose:

To evaluate the efficacy of nivolumab and comparison with dacarbazine (DTIC) on peritoneal carcinomatosis of malignant melanoma in mouse model.

Methods:

Mouse skin melanoma cells was injected under the capsule of the peritoneal surface in the left side of the abdomen. On postoperative day ten, mouses randomised into three groups. Group 1 Control, Group 2 HIPEC (Hyperthermic intraperitoneal chemotherapy) with DTIC and Group 3 HIPEC with Nivolumab. After the sacrification on postoperative day fifteen, peritoneum evaluated macroscopically and histopathologically by using peritoneal regression grading score (PRGS).

Results:

In the 15th day exploration, all animals developed extensive intraperitoneal tumor growth in Group 1. In Group 2 and Group 3 median tumor size was 0.7±0.3cm and 0.3±0.2cm respectively (p 0.023). Peritoneal carcinomatosis index (PCI) were significantly lower in Group 3 than other groups (p 0.019). The lowest total tumor nodules in group 3 was 4 ± 2. The PGRS score was found significantly lower in Group 3 than other groups (p 0.03). Lymphocytic response rate was found higher in the Group 3.

Conclusions:

It has been found that nivolumab significantly better than DTIC on peritoneal metastases of malign melanoma in mouse models. Nivolumab treatment gives promising results with pathological evidence in the treatment of metastatic disease of malignant melanoma.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Peritoneal Neoplasms / Peritoneum / Melanoma / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Diagnostic study Limits: Animals Language: English Journal: Acta cir. bras Journal subject: General Surgery / Procedimentos Cir£rgicos Operat¢rios Year: 2017 Type: Article Affiliation country: Turkey Institution/Affiliation country: Umraniye Training and Research Hospital/TR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Peritoneal Neoplasms / Peritoneum / Melanoma / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Diagnostic study Limits: Animals Language: English Journal: Acta cir. bras Journal subject: General Surgery / Procedimentos Cir£rgicos Operat¢rios Year: 2017 Type: Article Affiliation country: Turkey Institution/Affiliation country: Umraniye Training and Research Hospital/TR